公开(公告)号：EP3476860A1

公开(公告)日：2019-05-01

申请号：EP17815743.4

申请日：2017-06-23

申请人： Mogam Institute for Biomedical Research ,  Green Cross Corporation

发明人： KANG, Kwan-Yub ,  LEE, Seung-Hoon ,  OH, Injae ,  OH, Mee Sook ,  RYU, Jae Hwan ,  JO, Eui-Cheol ,  LEE, Ki-Nam ,  YANG, Sun-Ah

IPC分类号： C07K14/755 ,  C07K1/113 ,  C07K19/00 ,  C12P21/00

摘要： The present application provides a single-chain blood coagulation factor VIII including a B region which is partially deleted to contain at least four glycosylation sites, but not a heavy chain, a light-chain, and a region to be cleaved by proteases, or a single-chain blood coagulation factor VIII in which the A or B region has some residues pegylated. A single-chain blood coagulation factor VIII according to the present application not only retains intact therapeutic efficacy and can be easily produced on mass scale because of its single chain form, but also has an increased half-life in vivo through pegylation, thus enhancing convenience for patients as a therapeutic agent for hemophilia A and bringing about a reduction of medical expenses through reduction in production cost.

公开(公告)号：EP3476937A1

公开(公告)日：2019-05-01

申请号：EP17815750.9

申请日：2017-06-23

申请人： Mogam Institute for Biomedical Research

发明人： OH, Injae ,  LEE, Seung-Hoon ,  JO, Eui-Cheol ,  OH, Mee Sook ,  RYU, Jae Hwan ,  KIM, Yong Jae ,  KIM, So Ra ,  PARK, Jin-hyun

IPC分类号： C12N9/64 ,  C12N15/62 ,  C07K14/755 ,  A61K38/00

摘要： A chimera protein according to the present application has a significantly increased in vivo half-life when administered because of a vWF domain coupled to FVIII, such that when used as a hemophilia A therapeutic agent, convenience for patients can be increased and medical expenses can be reduced.